Dean Flotte testified in support of policies that would encourage and accelerate gene therapy for rare diseases, in a Feb. 29 hearing before the House Committee on Energy and Commerce’s Subcommittee on Health.

MD/PhD student Jillian Belgrad has received an award from the National Institute of Neurological Disorders and Stroke to study the pathology that drives the development of Huntington’s disease symptoms.  

Atalanta Therapeutics, a biotech founded by UMass Medical School and three faculty research scientists to pioneer treatment options for neurodegenerative diseases, has launched with financing by venture capital fund F-Prime Capital and strategic collaborations with Biogen and Genentech.

UMass Medical School postdoctoral associate Yasaman Gholamalipour, PhD, was awarded the Huntington’s Disease Society of America Berman-Topper Family HD Career Development Fellowship for 2020.

Neil Aronin, MD, led an afternoon of presentations detailing advances made by scientists at UMass Medical School in the quest to find a treatment for Huntington’s disease. CHDI Foundation President Robi Blumenstein accepted a plaque in recognition of the foundation’s $13 million in support of Huntington’s research at the medical school.